The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Document Type
Journal Article
Publication Date
3-3-2019
Journal
Contemporary Clinical Trials
DOI
10.1016/j.cct.2019.02.008
APA Citation
Roberts, S., Jain, S., Tremoulet, A., Kim, K., Burns, J., Anand, V., Anderson, M., Ang, J., Ansusinha, E., Arditi, M., Ashouri, N., Bartlett, A., Chatterjee, A., DeBiasi, R., Dekker, C., DeZure, C., Didion, L., Dominguez, S., El Feghaly, R., Erdem, G., Halasa, N., Harahsheh, A., Jackson, M., Jaggi, P., Jain, S., Jone, P., Kaushik, N., Kurio, G., Lillian, A., Lloyd, D., Manaloor, J., McNelis, A., Michalik, D., Newburger, J., Newcomer, C., Perkins, T., Portman, M., Romero, J., Ronis, T., Rowley, A., Schneider, K., Schuster, J., Tejtel, S., Sharma, K., Simonsen, K., Szmuszkovicz, J., Truong, D., Wood, J., & Yeh, S. (2019). The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.. Contemporary Clinical Trials, (). http://dx.doi.org/10.1016/j.cct.2019.02.008
Peer Reviewed
1
- Citations
- Policy Citations: 1
- Citation Indexes: 30
- Usage
- Abstract Views: 25
- Captures
- Readers: 70
Comments
Epub ahead of print